Propeller Health Receives FDA Clearance for the Propeller Platform

Propeller Health has gained the FDA 510(k) clearance to market its Propeller platform for use with GSK's dry powder inhaler Ellipta.

The device is designed to help patients and their physicians better understand asthma and COPD, and to improve the symptoms and effects of these chronic respiratory diseases.

The FDA clearance follows CE Mark and Health Canada registration for the device and system  earlier this year. — Cynthia Jessup